Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Method of assessing the efficacy of a test agent for modulating programmed death 1 (PD-1) signaling by using anti-phosphotyrosinylated PD-1 monoclonal antibodies

Method of assessing the efficacy of a test agent for modulating programmed death 1 (PD-1) signaling by using anti-phosphotyrosinylated PD-1 monoclonal antibodies

US Patent 12258409 · Granted Mar 25, 2025

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Injection molding to generate complex hydrogel geometries for cell encapsulation2025
T cell receptor constructs and uses thereof2025
Neoantigens and uses thereof2025
Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor 2025
Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor 2025
Methods for upregulating immune responses using combinations of anti-RGMb and an2024
KIR3DL3 as an HHLA2 receptor, anti-HHLA2 antibodies, and uses thereof2024
Antibody molecules to PD-1 and uses thereof2023
Antibody molecules to PD-1 and uses thereof2023
Neoantigens and uses thereof2023
Methods of treating cancer using LSD1 inhibitors in combination with immunothera2023
Compositions and methods for identification, assessment, prevention, and treatme2023